Docket No. 246424US8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Thomas NILSSON, et al.

SERIAL NO: New Application

GAU:

FILED:

Herewith

EXAMINER:

FOR:

A MEDICAL PRODUCT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SRIVAK, McCLELLAND, MAIER & TEUSTADT, P.C.

Bradley D. Lytle

Registration No. 40,073

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Thomas W. Barnes III, Ph.D.

Registration No. 52,595

DOCKET NO.: 246424US8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Thomas NILSSON, et al.

SERIAL NO: New Application

FILED:

HEREWITH

FOR:

A MEDICAL PRODUCT

STATEMENT OF RELEVANCY

Reference AW listed on the attached Form PTO 1449 is discussed at page 4, lines 22-25 of the specification.

Reference AX listed on the attached Form PTO 1449 is discussed at page 5, lines 8-11 of the specification.

Reference AY listed on the attached Form PTO 1449 is discussed at page 5, lines 11-13 of the specification.

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.		SERIAL NO.			
(Modified) PATENT AND TRADEMAR		OFFICE	246424US8	New Application				
			APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT			Thomas NILSSON, et al.					
			FILING DATE		GROUP			
			Herewith					
U.S. PATENT DOCUMENTS								
	CUMENT DA	ATE	NAME	CLASS	SUB CLASS			
AA								
AB								
AC								
AD		_						
AE								
AF								
AG								
AH							· · · · · · · · · · · · · · · · · · ·	
Al								
AJ								
AK								
AL								
AM								
AN						-	·	
FOREIGN PATENT DOCUMENTS								
DOCUMENT DATE			COUNTRY	TRANSLATION				
NU	MBER D		COUNTRY			YES NO		
AO								
AP								
AQ							·	
AR								
AS								
AT								
AU								
AV								
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
COLLEGE TER BEOORDELING VAN GENEESMIDDELEN MEDICINES EVALUATION BOARD; PUBLIC ASSESSMENT REPORT; "Spiriva 18 μg, inhalation powder in hard capsules"; May 21, 2002; pp. 1-28								
AX Guidance Manufact	Guidance for Industry; "Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products"; Chemistry, Manufacturing, and Controls Documentation; 1998							
AY Guidance	Guidance for Industry; "Stability Testing of Drug Substrances and Drug Products"; Draft Guidance B; 1998							
AZ					Additional References sheet(s) attached			
Examiner				Date Considered				
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								